Arch Oncology scores USD 105 Million for anti-CD47 med in solid tumors, multiple myeloma
Arch Oncology scored USD 105 million from new and old backers to expand the drug’s journey through the clinic and into new trials, having moved its anti-CD47 antibody into a phase 1/2 study.
Arch tests the drug alone in patients with multiple myeloma and alone and in combination with the chemotherapy drug paclitaxel in patients with select solid tumors. Next up, Arch intends to evaluate AO-176 alongside Merck’s PD-1 drug Keytruda in solid tumors and combination with other drugs for multiple myeloma, namely Velcade (bortezomib) and dexamethasone. Moreover, the company d...